Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ANIX - Anixa Biosciences Inc


IEX Last Trade
2.53
0   0%

Share volume: 5
Last Updated: Fri 27 Dec 2024 07:52:24 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.25%

PREVIOUS CLOSE
CHG
CHG%

$2.53
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
22%
Profitability 25%
Dept financing 5%
Liquidity 50%
Performance 16%
Company vs Stock growth
vs
Performance
5 Days
-0.39%
1 Month
-22.36%
3 Months
-19.44%
6 Months
7.98%
1 Year
-34.77%
2 Year
-34.61%
Key data
Stock price
$2.53
P/E Ratio 
0.00
DAY RANGE
$2.53 - $2.53
EPS 
$0.00
52 WEEK RANGE
$2.25 - $5.13
52 WEEK CHANGE
-$33.76
MARKET CAP 
106.902 M
YIELD 
N/A
SHARES OUTSTANDING 
32.006 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
09/06/2024
BETA 
0.68
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$74,812
AVERAGE 30 VOLUME 
$80,336
Company detail
CEO: Amit D. Kumar
Region: US
Website: anixa.com
Employees: 5
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Anixa Biosciences, Inc. develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company is also developing immuno-therapy drugs against cancer.

Recent news